Edition:
United Kingdom

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

74.38EUR
1:38pm BST
Change (% chg)

€-0.29 (-0.39%)
Prev Close
€74.67
Open
€74.72
Day's High
€75.25
Day's Low
€74.38
Volume
1,846,888
Avg. Vol
2,515,857
52-wk High
€86.39
52-wk Low
€62.88

Chart for

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality... (more)

Overall

Beta: 0.93
Market Cap(Mil.): €108,903.00
Shares Outstanding(Mil.): 1,262.50
Dividend: 2.96
Yield (%): 3.43

Financials

  SASY.PA Industry Sector
P/E (TTM): 23.32 30.93 32.76
EPS (TTM): 3.70 -- --
ROI: 5.69 15.07 14.61
ROE: 8.50 16.59 16.33

Sanofi pledges to keep up its restructuring efforts

(This version of the Sept. 14th story has been refiled to add dropped words in fifth paragraph)

18 Sep 2018

Sanofi pledges to keep up its restructuring efforts

(This Sept 14 story has been refiled to add dropped words in fifth paragraph.)

18 Sep 2018

REFILE-UPDATE 1-Sanofi pledges to keep up its restructuring efforts

PARIS, Sept 14 Sanofi will continue to implement cost savings after having reached a 1.5 billion euros ($1.75 billion) cost reduction target a year ahead of expectations, and added that several of its key drugs were selling well.

18 Sep 2018

Sanofi pledges to keep up restructuring efforts

PARIS, Sept 14 Sanofi said it would continue to implement cost savings after having reached a 1.5 billion euros ($1.75 billion) cost reduction target a year ahead of expectations.

14 Sep 2018

Bayer's pharma unit head Weinand quits to join Sanofi

FRANKFURT Bayer, which is revamping its drug development activities, is losing the head of its pharmaceuticals division Dieter Weinand, who will join Sanofi to stem a decline in prices in the French drugmaker's anti-diabetics and established drugs.

13 Sep 2018

Bayer's pharma unit head Weinand quits to join Sanofi

FRANKFURT Bayer , which is revamping its drug development activities, is losing the head of its pharmaceuticals division Dieter Weinand, who will join Sanofi to stem a decline in prices in the French drugmaker's anti-diabetics and established drugs.

13 Sep 2018

UPDATE 1-Bayer's pharma unit head Weinand quits to join Sanofi

FRANKFURT, Sept 13 Bayer, which is revamping its drug development activities, is losing the head of its pharmaceuticals division Dieter Weinand, who will join Sanofi to stem a decline in prices in the French drugmaker's anti-diabetics and established drugs.

13 Sep 2018

Bayer's pharma unit head Weinand quits to join Sanofi

FRANKFURT, Sept 13 The head of Bayer's pharmaceuticals division Dieter Weinand will quit to joint Sanofi to head the French drugmaker's new Primary Care unit.

13 Sep 2018

Sanofi to pay more than $25 million to resolve corruption charges: SEC

WASHINGTON French pharmaceutical giant Sanofi will pay more than $25 million to settle charges that its Kazakhstan and Middle East subsidiaries made corrupt payments to win business, the top U.S. securities regulator said on Tuesday.

04 Sep 2018

Sanofi to pay more than $25 million to resolve corruption charges - SEC

WASHINGTON French pharmaceutical giant Sanofi will pay more than $25 million (19.47 million pounds) to settle charges that its Kazakhstan and Middle East subsidiaries made corrupt payments to win business, the top U.S. securities regulator said on Tuesday.

04 Sep 2018

Earnings vs. Estimates